Novartis AG
NVS
143.12
-0.16
-0.11%
Novartis AG
US · NVS
#65 by market cap
Listed 1970
143.12
-0.16
-0.11%
Live - 5344 symbols - heartbeat 161s ago
· 2026-10-08 16:00
Pre-market
142.80
-0.34%
After-hours
143.11
-0.01%
Overnight
142.49
-0.55%
- Market cap
- 272.03B
- P/E (TTM)i
- 21.62
- P/Bi
- 6.55
- EPSi
- 7.15
- Div yieldi
- 3.31%
- 52W posi
- 53%
Reader sentiment
Are you bullish or bearish on NVS?
Anonymous reader poll. Unscientific, not investment advice.
Recent news
-
Novartis AG (NVS.US) secures approval in China for a new indication for its blockbuster radiopharmaceuticalZhitong Finance · 2026/8/26
-
Rating change
Morgan Stanley Maintains Novartis AG(NVS.US) With Buy Rating, Raises Target Price to $170Market Newswire · 2026/3/26
-
Setback for the second time in a week! Novartis (NVS.US) sees its blockbuster heart disease drug fail in Phase III trials, causing a sharp drop in share price; Amgen (AMGN.US) suffers collateral damage.Zhitong Finance · 2026/9/7
-
Rating change
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Raises Target Price to $180Market Newswire · 2026/6/12
-
Rating change
Bernstein Initiates Novartis AG(NVS.US) With Hold RatingMarket Newswire · 2026/3/20
-
Rating change
Argus Research Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $180Market Newswire · 2026/3/11
-
Rating change
HSBC Maintains Novartis AG(NVS.US) With Sell Rating, Raises Target Price to $112Market Newswire · 2025/12/10
-
Rating change
BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Raises Target Price to $177.37Market Newswire · 2026/6/11
-
Rating change
Barclays Initiates Novartis AG(NVS.US) With Hold RatingMarket Newswire · 2026/1/7
-
BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Raises Target Price to $185.56Market Newswire · 2026/9/7
-
Rating change
BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Cuts Target Price to $175.32Market Newswire · 2026/3/27
-
Company notice
SAAG CONSOLIDATED (M): Britac Berhad Disposal of 350,000 shares of HK$1.00 each representing 70% of the total issued and paid up share capital of Britac (China) Limited by Britac-Saag (S) Pte Ltd, a wholly owned subsidiary of Britac Berhad to NVS Invest &Bursa Malaysia · 2003/4/22
-
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $180Market Newswire · 2026/9/9
-
Rating change
Argus Research Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $160Market Newswire · 2026/6/6
-
Rating change
BofA Securities Maintains Novartis AG(NVS.US) With Buy RatingMarket Newswire · 2026/7/22
-
Company notice
SAAG CONSOLIDATED (M): Britac Berhad ("Britac") - Disposal of 350,000 shares of HK$1.00 each representing 70% of the total issued and paid up share capital of Britac (China) Limited by Britac-Saag (S) Pte Ltd, a wholly owned subsidiary of Britac to NVSBursa Malaysia · 2003/4/17
-
Rating change
Morgan Stanley Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $143Market Newswire · 2025/12/3
-
Rating change
BofA Securities Upgrades Novartis AG(NVS.US) to Buy Rating, Raises Target Price to $177.65Market Newswire · 2026/3/23
-
BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Announces Target Price $172.96Market Newswire · 2026/9/1
-
Rating change
BofA Securities Maintains Novartis AG(NVS.US) With Buy Rating, Cuts Target Price to $177.61Market Newswire · 2026/3/24
-
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating, Maintains Target Price $180Market Newswire · 7/27
-
Strong sales of innovative drugs offset the impact from generics! Novartis AG (NVS.US) Q2 results beat expectations, signaling a return to growth trajectory.Zhitong Finance · 7/21
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-10-08 16:00:15 · For reference only, not investment advice and not tailored to your situation.